Koshida K, Naito K, Hisazumi H
Department of Urology, School of Medicine, Kanazawa University.
Hinyokika Kiyo. 1987 Oct;33(10):1703-7.
The clinical application of enzyme immunoassay (EIA) for prostatic acid phosphatase (PAP) is reported. PAP concentration was measured by an IQ(Bio)PAP-AELIA kit. Serum samples were collected from 20 healthy individuals, 31 patients with benign prostatic hypertrophy, 14 patients with prostatis, 23 patients (47 samples) with prostatic cancer and 29 patients with various other malignancies. The coefficients of variation (%CV) in intraassay and interassay ranged from 2.3 to 4.4%, and from 3.0 to 3.6%, respectively. The recovery rate in the dilution test and recovery test were 106.2 +/- 8.9% and 101.3 +/- 6.9% respectively. A significant correlation (r = 0.994, p less than 0.01) was observed between EIA and RIA methods in the prostatic cancer patients. PAP concentration was elevated above 2.0 ng/ml in 0/2 (0%) of the treated patients with stage B prostatic cancer, 1/5 (20%) of those with stage C, 6/16 (38%) of those with stage D, and in 4/5 (80%) of the untreated patients with stage D prostatic cancer. False positive results were seen in 2/31 (6%) of the patients with benign prostatic hypertrophy, 3/14 (21%) with prostatis and 3/29 (10%) of the patients with various other malignancies. In the majority of the false positive cases, elevated levels were only just above the normal value. In conclusion, the PAP level measured by this EIA kit was correlated with the clinical response to hormone therapy for prostatic cancer.
本文报道了酶免疫分析法（EIA）检测前列腺酸性磷酸酶（PAP）的临床应用。采用IQ(Bio)PAP - AELIA试剂盒测定PAP浓度。收集了20名健康个体、31例良性前列腺增生患者、14例前列腺炎患者、23例前列腺癌患者（47份样本）以及29例其他各类恶性肿瘤患者的血清样本。批内变异系数（%CV）范围为2.3%至4.4%，批间变异系数范围为3.0%至3.6%。稀释试验和回收试验的回收率分别为106.2±8.9%和101.3±6.9%。在前列腺癌患者中，EIA法与放射免疫分析法（RIA）之间观察到显著相关性（r = 0.994，p＜0.01）。B期前列腺癌治疗患者中PAP浓度高于2.0 ng/ml的比例为0/2（0%），C期为1/5（20%），D期为6/16（38%），未治疗的D期前列腺癌患者中该比例为4/5（80%）。良性前列腺增生患者中有2/31（6%）出现假阳性结果，前列腺炎患者中有3/14（21%），其他各类恶性肿瘤患者中有3/29（10%）。在大多数假阳性病例中，升高水平仅略高于正常值。总之，该EIA试剂盒检测的PAP水平与前列腺癌激素治疗的临床反应相关。
